Rational selection of antigenic targets for Group A Streptococcus vaccine: updates, challenges and opportunities
Group A Streptococcus (GAS) remains a major global health challenge, causing over half a million deaths annually. Despite nearly a century of research, no licensed vaccine is currently available, due to antigenic diversity, complex host-pathogen interactions, risk of autoimmunity and lack of clear correlates of protection. This review discusses recent advances in GAS vaccine research, highlights key challenges and outlines criteria and emerging opportunities for antigen selection.
Authors
- István Tóth (ORCID: https://orcid.org/0000-0002-4572-397X)
- Mariusz Skwarczyński (ORCID: https://orcid.org/0000-0001-7257-807X)
- Melaku Ashagrie Belete (ORCID: https://orcid.org/0000-0002-0706-9903)
- Rachel Stephenson
Institutions
- The University of Queensland (AU)
- Wollo University (ET)
Publication Details
- Journal
- npj Vaccines
- Published
- 2026-04-17
- DOI
- https://doi.org/10.1038/s41541-026-01445-5
- Primary Topic
- Streptococcal Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Health and Medical Research Council